By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen Research & Development 

3210 Merryfield Row

San Diego  California  92121  U.S.A.
Phone: 858-450-2000 Fax: n/a


SEARCH JOBS
At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.

As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:

• cardiovascular and metabolism,
• immunology,
• infectious diseases and vaccines,
• neuroscience, and
• oncology.

We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.

We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.

Website: http://www.janssenrnd.com/our-company

Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research.
The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.

http://www.janssenlabs.com/about/overview


Key Statistics


Email:
Ownership: Private

Web Site: Janssen R&D
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
Janssen R&D Funds New Global Leadership Initiative On Brain Health 7/12/2016 7:33:12 AM
Janssen R&D And Johnson & Johnson (JNJ) To Provide Webcast Presentation On Phase 3 Data For DARZALEX (Daratumumab) And The Janssen Immuno-Oncology Strategy And Portfolio 7/7/2016 7:25:54 AM
Janssen R&D Release: Canagliflozin Phase 2 Study Demonstrates Glycemic Improvements In Adults With Type 1 Diabetes 6/14/2016 11:56:39 AM
Janssen R&D Release: New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management 6/13/2016 11:12:46 AM
Janssen R&D Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma 6/10/2016 8:58:12 AM
New Janssen R&D Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease 6/8/2016 7:30:20 AM
ASCO2016: Janssen R&D Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma 6/6/2016 10:07:08 AM
Janssen R&D Release: New Phase 3 Study Findings Show STELARA Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn's Disease 5/24/2016 7:38:19 AM
Janssen R&D Discontinues Fulranumab Phase III Program; Terminates Agreement with Amgen (AMGN) 4/1/2016 6:02:13 AM
Janssen Research & Development Release: First Phase 3 Trial Of Daratumumab In Combination With Standard Therapy In Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint In Planned Interim Analysis 3/30/2016 10:54:59 AM
12345678910
//-->